Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 6/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517364 | 0.90 | ADH1A (0.53) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL6517359 | 0.90 | ADH1A (0.53) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL6390745 | 0.89 | PDGFRB (0.47) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL5864896 | 0.88 | FLT3 (0.48) | DRD2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL2399027 | 0.85 | MEN1 (0.49) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL7672527 | 0.84 | MEN1 (0.47) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL6204595 | 0.84 | MEN1 (0.47) | DRD2DRD3HRH4MEN1KMT2A | |
| SCHEMBL6514946 | 0.83 | ADH1A (0.52) | DRD2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL6514942 | 0.83 | ADH1A (0.52) | DRD2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL5865145 | 0.83 | P4HB (0.51) | KDM4EADH1AKITFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038249-A1 | Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-02-17 | — | — | US | claimed |
| US-20040138195-A1 | Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-07-15 | — | — | US | claimed |
| US-7064117-B2 | Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-06-20 | — | — | US | disclosed |
| US-20050038249-A1 | Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-02-17 | — | — | US | disclosed |
| US-20040138195-A1 | Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138195-A1 | Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium | IDH1, HIF1AN, CA2 | DRD2 2758/4885DRD3 2732/4885HRH4 595/4885 |
| US-20050038249-A1 | Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium | CA2, HIF1AN, PPOX | DRD2 2776/4885DRD3 2913/4885HRH4 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.